Not yet recruiting
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
NCT07742527
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
Not specified